Loading clinical trials...
Loading clinical trials...
A Multi-center, Double-blind, Randomized, Placebo-controlled Study of TT223 in Patients With Type 2 Diabetes Treated With Metformin and/or TZD
This trial is designed to show the effect of treatment with TT223 or placebo on blood glucose control after 12 weeks of treatment with a 6 month follow-up. TT223 is administered by injection once daily to patients currently treated with Metformin and/or Thiazolidinedione.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Artesia, California, United States
Los Angeles, California, United States
Santa Ana, California, United States
Torrence, California, United States
Walnut Creek, California, United States
DeLand, Florida, United States
Bloomingdale, Illinois, United States
Grand Rapids, Michigan, United States
St Louis, Missouri, United States
Las Vegas, Nevada, United States
Start Date
August 1, 2008
Primary Completion Date
December 1, 2009
Completion Date
December 1, 2009
Last Updated
June 21, 2013
87
ACTUAL participants
TT223 with Metformin and/or TZD
DRUG
Placebo with Metformin and/or TZD
DRUG
Lead Sponsor
OPKO Health, Inc.
NCT06959901
NCT06574035
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06861062